Investors envisage further Ipsen growth after latest results

French drugmaker Ipsen (Euronext: IPN) followed up its outstanding 2017 financial results – that included a 21% rise in group sales – with the promise that more good times are to come.

Investors clearly believe the message, too, with shares in the company closing 5% up on Thursday, at 115.05 euros.

A 26% rise in specialty care sales were responsible for the rise across the group to a total of 1.91 billion euros ($2.4 billion), while for the fourth quarter of 2017, the group sales figure was 519.2 million euros, a 21% increase compared to the last quarter of 2016.